Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-SOFT cognitive function substudy in premenopausal breast cancer
ACTRN12607000542493Phase 3Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Oct 2008
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, exemestane and goserelin in breast cancer (3 arms), sponsored by Breast Cancer Trials. Primary endpoint: Change in cognitive function over 1 year: tamoxifen versus tamoxifen plus ovarian function suppression. Started Oct 2008; status: terminated.
02
Drugs
tamoxifenexemestanegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000542493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000542493.